met

Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints

SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…

3 months ago

Water Crisis to Water Security: The Art of Living’s Scalable Model for a Water Positive India

BENGALURU, India, Aug. 26, 2025 /PRNewswire/ -- Water is India's lifeline - and its looming crisis. With 80% of the…

4 months ago

Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients

August 21, 2025 01:30 ET  | Source: NICOX SA Press Release Nicox Announces Positive Results from the NCX 470 Phase…

4 months ago

IOC President Coventry visits Singapore for World Aquatics Championships

30 July 2025 - During a three-day visit to the city-state, IOC President Kirsty Coventry attended the World Aquatics Championships; met athletes, partners…

5 months ago

WIKATI Accredited with ICEF Agency Status

HYDERABAD, India, July 8, 2025 /PRNewswire/ -- WIKATI Education Services LLC has been awarded the ICEF Agency Status (IAS), a…

6 months ago

FAIR PLAY MENARINI INTERNATIONAL AWARD, A WAVE OF EMOTIONS MARKS THE 29TH EDITION

FIESOLE, Italy, July 4, 2025 /PRNewswire/ -- A night suspended between history and legend, dedicated to the most authentic values…

6 months ago

OSE Immunotherapeutics met jour linformation sur les procdures en cours

OSE Immunotherapeutics provides an update on ongoing proceedings NANTES, France, July 2, 2025, 8 AM – OSE Immunotherapeutics SA (ISIN:…

6 months ago

Olympic Refuge Foundation unveils plans to step up support for millions of displaced people around the world with new strategy

03 June 2025 - The Olympic Refuge Foundation (ORF) Board met at Olympic House in Lausanne this week, to review the success of…

7 months ago

Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant…

7 months ago